The tweet was deleted by the author.
But we saved everything 🙂.
Tyra Biosciences announced the publication of a new scientific paper in the Journal of Medicinal Chemistry examining the biology, molecular design, and therapeutic implications of FGFR3-selective inhibitors in the treatment of urologic cancers and achondroplasia.
The company shared the development as part of its ongoing research efforts in targeted therapy, focusing on advancing the understanding of inhibitors that may have future clinical applications.
View post on X Loading...
Tyra Biosciences has previously advanced therapies targeting FGFR3 to address achondroplasia and select urologic cancers, according to an earlier update on its research efforts. The company highlighted progress in FGFR3-driven treatment strategies. These initiatives form part of its ongoing focus on next-generation targeted therapies.